Shares of Shilpa Medicare Ltd rallied 4% on Monday, 11 August, after the company announced securing approval from the Central Drugs Standard Control Organisation (CDSCO) for Nor Ursodeoxycholic Acid Tablets 500 mg.

Shilpa Medicare stated in an exchange filing that the NorUDCA pills 500 mg are used to treat Non-Alcoholic Fatty Liver Disease (NAFLD), and that the approval is a significant step forward in the country’s unique NAFLD therapy. The NorUDCA is India’s first-in-class therapy for NAFLD.

With this permission, Shilpa Medicare will be the first business to launch this medicine in any area of the world to treat NAFLD.

In its regulatory filing, the company said, “The approval reinforces Shilpa Medicare’s commitment to addressing unmet medical needs in Hepatology, through innovation and evidence-based solutions.”

NAFLD is the most common liver ailment in the world, affecting 25% of the worldwide population or approximately 1.2 billion people, including up to 188 million people in India alone.

The company added, “These results collectively demonstrate a significant improvement in both liver structure and function, confirming NorUDCA’s superior efficacy compared to placebo in NAFLD.”

NorUDCA’s choleretic and anti-inflammatory qualities can improve bile flow, reduce hepatic inflammation, and potentially treat NAFLD and other cholestatic liver illnesses, according to the business.

At 12:52 pm, the shares of Shilpa Medicare were trading 3.30% higher at Rs 859.45 on NSE.

Unlock profitable opportunities every day! Unicorn Signals provides actionable intraday trading signals for stocks and futures. Don’t miss out – download Unicorn Signals and start winning now!